Cytogen completes merger of wholly owned unit GenomeCare

Bitget2026/10/01 06:38

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cytogen completed the merger of wholly owned subsidiary GenomeCare on Oct. 1, 2026.
The deal used a 1:0 merger ratio, issuing no new shares and leaving major shareholder stakes unchanged.
Opposition notices came from 963 shareholders covering 236,678 shares, equal to 1.02% of shares outstanding.
No creditor objections were filed during the Aug. 31 to Sept. 30 period.
Pro forma balance sheet at June 30, 2026 showed combined assets of 52,527,571,847 won, liabilities of 20,335,093,013 won.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytogen Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261001000367), on October 01, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cytogen completes merger of wholly owned unit GenomeCare

You may also like

Crypto prices